MS Fighters TT

12/02/2026

06/12/2025

Feel what MS spasticity is like and how to manage it: https://bit.ly/3UrvoJw

06/12/2025

Mssftt - Multiple Sclerosis Support Foundation of Trinidad & Tobago

15/11/2025

Try these 5 effective stretches for MS spasticity today: https://bit.ly/3UQrDxz

02/11/2025

Around 75% of people with MS in the UK are women. The majority are aged between 20 and 40 at the time of their diagnosis. This means that most women with MS will experience menopause at some point after their MS diagnosis.

This , we’re sharing a blog from Imogen, a PhD student at Queen Mary University of London’s Centre for Preventive Neurology.

Her research explores the links between menopause and MS, and the health inequalities that impact women: https://buff.ly/dhIRiwP

23/10/2025

Clinical trial news. 🔬⬇️

CCMR2 was a phase 2 trial run by researchers at our Cambridge Centre for Myelin Repair. 70 people with relapsing MS took part over six months.

Early results suggest a combination of two existing drugs may be able to boost myelin repair in relapsing MS.

Dr Nick Cunniffe, who led the trial, said “I am increasingly sure that remyelination is part of the solution to stopping progressive disability in MS.” 💬

Read more about the CCMR2 trial results on our website: https://mssoc.uk/4nOALir

23/10/2025

01/10/2025

In a major scientific leap, researchers have identified two gut bacteria strains that may trigger multiple sclerosis (MS) — opening the door to new treatments or even prevention.

👥 Studying 81 identical twin pairs (where one had MS and the other didn’t), scientists at Ludwig Maximilian University of Munich found key differences in their gut microbiomes.

🚨 The culprits?

Eisenbergiella tayi and Lachnoclostridium — both significantly more common in those with MS. When introduced to mice, these strains triggered MS-like symptoms.

💡 This is the strongest evidence yet linking the gut to MS. By targeting the microbiome, we may soon be able to slow—or stop—MS in its tracks.

🦠 The gut-brain connection just got even more real.

28/09/2025

Hopeful ☺️

Clinical trial news. 🔬⬇️

CCMR2 was a phase 2 trial run by researchers at our Cambridge Centre for Myelin Repair. 70 people with relapsing MS took part over six months.

Early results suggest a combination of two existing drugs may be able to boost myelin repair in relapsing MS.

Dr Nick Cunniffe, who led the trial, said “I am increasingly sure that remyelination is part of the solution to stopping progressive disability in MS.” 💬

Read more about the CCMR2 trial results on our website: https://mssoc.uk/4nOALir

14/09/2025

In a major scientific leap, researchers have identified two gut bacteria strains that may trigger multiple sclerosis (MS) — opening the door to new treatments or even prevention.

👥 Studying 81 identical twin pairs (where one had MS and the other didn’t), scientists at Ludwig Maximilian University of Munich found key differences in their gut microbiomes.

🚨 The culprits?

Eisenbergiella tayi and Lachnoclostridium — both significantly more common in those with MS. When introduced to mice, these strains triggered MS-like symptoms.

💡 This is the strongest evidence yet linking the gut to MS. By targeting the microbiome, we may soon be able to slow—or stop—MS in its tracks.

🦠 The gut-brain connection just got even more real.